Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Early Phase 1
1(16.7%)
6Total
Phase 1(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03664661Phase 1Unknown

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT03661554Early Phase 1Unknown

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

Role: lead

NCT03542799Phase 1Unknown

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT03540303Phase 1Unknown

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Role: collaborator

NCT03322735Phase 1Unknown

Study of BCMA CAR-T in Multiple Myeloma

Role: collaborator

NCT03263208Phase 1Unknown

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Role: collaborator

All 6 trials loaded